R&D | April 14, 2026
Aragen launches ChemiSHE, India’s first women-led chemistry synthesis lab
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Paves the way for next-gen ultra-precise gas sensing
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
